Abstract
The robust growth in the pharmaceutical markets of emerging world economies
has outpaced the overall growth of the global pharmaceutical market. The
emerging markets are being driven by rapidly growing economies of these
countries, increasing per capita income, increasing prevalence of lifestyle
diseases due to rapid urbanization, and low-cost factors. Mainly due to strong
performance in the emerging pharmaceutical markets, the global pharmaceutical
market is expected to reach US$ 1,020 Billion by the end of 2012. This
research study provides extensive and coherent information about
pharmaceutical markets in emerging countries. It also gives a detailed
statistical and analytical review on the demographics, macroeconomic
indicators, disease profile, key drivers and restraints of the emerging
pharmaceutical markets.
The report covers all the key aspects of the various emerging pharmaceutical
markets and has broadly outlined the factors that are affecting the industry.
The report also provides current and predicted future performance of the
pharmaceutical market in different regions of the world. Key countries of each
region have been covered and the status of pharmaceutical industry has been
provided. Moreover, the report provides information regarding therapeutic
segments and key companies. Besides, detail information regarding generics,
patented drugs and prescription drugs have been included for all the
countries. It provides segment level analysis of the industry along with
emerging trends on intellectual property, market opportunities, research
collaborations, partnership activities, and guidelines for establishing new
ventures. The research will help consultants, industry analysts, and vendors
to get in-depth knowledge of the current, past, and future performance of the
emerging pharmaceutical markets.
The global pharmaceutical market experienced exponential growth over the past
decade but is now witnessing a slump. This slump is attributed to saturation
in key markets such as United States and Western Europe, patent expiry of key
drug formulations and a static economy. On the other hand, many growing
economies in the developing regions of Asia and Latin America are witnessing a
continuous high growth rate in the pharmaceutical sector. In the coming years,
these markets are expected to continue their robust growth owing to various
factors such as increasing prevalence of lifestyle diseases, rise in spending
on healthcare and increased access and affordability to healthcare
services.This seismic shift in the pharmaceutical markets of the world, away
from the major developed powers of the U.S., Japan, France, Germany, Italy,
United Kingdom, Spain and Canada to a set of new, dynamic, fast-growing
emerging economies of China, Brazil, Russia, India, Mexico, Turkey, and South
Korea has created new dynamics. These seven emerging markets of the
pharmaceutical sector have been termed as ‘pharmerging markets’.
Apart from these E7 economies, many other emerging markets have been
recognized as interesting destinations for the major global pharmaceutical
players.Unlike the developed world, where health systems provide a more
uniform coverage level, the emerging pharmaceutical markets have wide regional
health expenditure differences within them. Moreover, recent major
developments and global recession have driven disparate rates of evolution in
each of these countries. Unlike the pharmaceutical market of United States and
Western Europe, the emerging markets are characterized by diverse therapeutic
segments, different and complex regulatory law and a fragmented market. The
worldwide economic crisis has also added a new layer of complexity to the
already challenging environment.
Thus, the need for action and informed direction has never been greater. Apart
from the BRIC nations (Brazil, Russia, India and China), positive developments
in other parts of the world are also reshaping the pharmaceutical sector. In
regions such as Latin America and Asia, Eastern Europe and North Africa, a new
set of emerging economies are now rapidly rising. A further 13 nations in
these regions have now reached a threshold of economic development and volume
of future growth that warrant close and immediate scrutiny. Collectively, the
emerging markets undoubtedly offer high potential, with rising GDPs, expanding
access to healthcare and an improving IP and regulatory environment in many
cases. Nevertheless, these markets are fraught with uncertainty and hurdles.
Local companies are strong and entrenched, domestic products well-established,
and generics dominate the market in a growing number of countries. Patients
invariably bear the highest share of healthcare spend, making issues of
willingness and ability to pay key in these low income countries.
About Select Biosciences
Select Biosciences provides focused market reports, custom consultancy,
recruitment, training courses and conferences to the biomedical marketplace.
Select Biosciences was established in 1999 to provide scientific consultancy
services to the biomedical industry.
From organising just three conferences in 2004, Select Biosciences now
organise around 100 conferences, training courses and tutorials every year,
across Europe, the USA and Asia.
In 2010 Select Biosciences won the coveted Queen' s Award for Enterprise,
acknowledging our eleven-fold growth in overseas sales over six years. This is
a tremendous boost for our company as we continue to seek new markets and
opportunities for further expansion over the coming years.
Table of Contents
1. OVERVIEW
1.1 STATEMENT OF REPORT
The robust growth in the pharmaceutical markets of emerging world economies
has outpaced the overall growth of the global pharmaceutical market. The
emerging markets are being driven by rapidly growing economies of these
countries, increasing per capita income, increasing prevalence of lifestyle
diseases due to rapid urbanization, and low-cost factors. Mainly due to strong
performance in the emerging pharmaceutical markets, the global pharmaceutical
market is expected to reach US$ 1020 Billion by the end of 2012.
This research study provides extensive and coherent information about
pharmaceutical markets in emerging countries. It also gives a detailed
statistical and analytical review on the demographics, macroeconomic
indicators, disease profile, key drivers and restraints of the emerging
pharmaceutical markets. It covers all the key aspects of the various emerging
pharmaceutical markets and has broadly outlined the factors that are affecting
the industry. The report also provides current and predicted future
performance of the pharmaceutical market in different regions of the world.
Key countries of each region have been covered and the status of
pharmaceutical industry has been provided. Moreover, the report provides
information regarding therapeutic segments and key companies. Besides, detail
information regarding generics, patented drugs and prescription drugs have
been included for all the countries. It provides segment level analysis of the
industry along with emerging trends on intellectual property, market
opportunities, research collaborations, partnership activities, and guidelines
for establishing new ventures.
The research will help consultants, industry analysts, and vendors to get
in-depth knowledge of the current, past, and future performance of the
emerging pharmaceutical markets.
1.2 SCOPE OF THE REPORT
The principal objectives of this analysis are to:
- Discuss viable market prospects through the identification of high-growth
opportunities in the emerging markets of the pharmaceutical sector.
- Examine the key dynamics that influence each individual market.
- Discuss the manufacturing advances, collaborations and major players in
important pharmaceutical markets.
- Obtain an understanding of the regulatory governance and local laws that
influences the policies in this sector.
- Identify the therapeutic segments and important local products for each
market.
- Discuss the important drivers that promote and restrict these emerging
pharmaceutical markets with an in-depth analysis of various sectors such as
investment, intellectual property regulations including future predictions for
growth.
Market figures regarding the current value of the emerging pharmaceutical
industry markets are taken from the most recently available data of the global
medical products industry.
This report will cover the following categories of the pharmaceutical markets:
- Demographics and socioeconomic status of each specific market.
- Major therapeutic segments.
- Comparison of worldwide trends towards generics with the emerging
marketing.
- Collaborations and partnerships
- Generics opportunities
- Regulatory framework and local laws
- Leading formulations of each specific market.
- Overview of the intellectual property regulation
- Research and development
- Key players in the each emerging market.
This study contains the latest statistics and figures for measuring growth and
trends within the marketplace. In addition, a discussion on each market
identified as having important role in the future global pharmaceutical market
is made. India, China, Russia and markets of the near and far east have been
discussed in detail to provide the reader with a deeper understanding of the
dynamics of each specific country.
This study's aims are to:
- Assess the pharmaceutical industry market drivers and bottlenecks, from
the perspective of the medical and scientific communities.
- Discuss the potential benefits of each of the emerging pharmaceutical
market for various sectors of the industry.
- Establish the current total market size and future growth of the various
pharmaceutical industry markets of Asia and Latin America and analyze the
current size and growth of various segments.
- Provide current and forecasted market shares by company.
- Discuss profit/business opportunities by imaging segments.
- Provide strategic recommendations for near term business opportunities.
1.3 SCOPE OF THE REPORT
The emphasis in this report is on those countries considered to be the
emerging pharmaceutical markets of the world, such as India, China, Russia,
South Korea, Latin America (Brazil, Mexico, Venezuela, Columbia, Peru,
Argentina, Chile), Eastern Europe (Poland, Czech Republic, Romania, Slovenia),
Near East (Egypt, Turkey, Saudi Arabia, Israel, Jordan, UAE, Lebanon, and
Kuwait). This report analyzes the markets mentioned above. What's more, this
examination defines the dollar volume of sales in the U.S. market and analyzes
the factors that influence the size and growth of the market segments. The
study surveys all companies known to be marketing, manufacturing or developing
nutraceutical technologies in the U.S. for the selected segments. Effort has
also been made to include sections on smaller companies located around the
world.
1.4 METHODOLOGY
Company-specific information is obtained mainly from industry trade
publications, academic journals, news and research articles, press releases
and corporate websites, as well as annual reports for publicly-held firms.
Additionally, sources of information include the non-governmental
organizations (NGOs) such as the World Health Organization (WHO) and
governmental entities like the U.S. Department of Health and Human Services
(HHS) and U.S. federal agencies such as the National Institutes of Health
(NIH), the Food and Drug Administration (FDA) and the Centers for Disease
Control and Prevention (CDC). Where possible and practicable, the most recent
data available have been used.
1.5 EXECUTIVE SUMMARY
The global pharmaceutical market experienced exponential growth over the past
decade but is now witnessing a slump. This slump is attributed to saturation
in key markets such as United States and Western Europe, patent expiry of key
drug formulations and a static economy. On the other hand, many growing
economies in the developing regions of Asia and Latin America are witnessing a
continuous high growth rate in the pharmaceutical sector. In the coming years,
these markets are expected to continue their robust growth owing to various
factors such as increasing prevalence of lifestyle diseases, rise in spending
on healthcare and increased access and affordability to healthcare services.
This seismic shift in the pharmaceutical markets of the world, away from the
major developed powers of the U.S., Japan, France, Germany, Italy, United
Kingdom, Spain and Canada to a set of new, dynamic, fast-growing emerging
economies of China, Brazil, Russia, India, Mexico, Turkey, and South Korea has
created new dynamics. These seven emerging markets of the pharmaceutical
sector have been termed as ‘pharmerging markets’.
